Motilal Oswal recommended Neutral rating on Divis Laboratories with a target price of Rs 7720 in its research report dated August 02, 2026.

Discover the Divis Labs Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

In the past month, Divi's Labs outperformed the market by soaring 25 per cent, as against a 1.2 per cent rise in the BSE Sensex.

Divi's Laboratories stock reached a new record high in July 2026. Chart patterns indicate continued upward momentum for the pharma stock. Short-term traders can consider buying the stock for a target ...

As the market opens later today, investors will keenly observe the trading behavior of Divis Labs shares, particularly as they commence trading ex-dividend, often leading to initial price adjustments ...

Real-time updates on Divis Laboratories share price. Check out the detailed analysis of the company in this live blog.

Divi's Laboratories Q1 FY27 net profit jumps 65.6% to ₹902 crore, revenue up 27.8%. Beats CNBC-TV18 estimates with strong ...

Jefferies maintains a 'Buy' rating and raises the target price to Rs 10,200, implying 27% upside. Here's what drove the earnings beat, margin expansion, custom synthesis growth and peptide opportunity ...

Divi's Laboratories Ltd (NSE:DIVISLAB) is set to release its Q2 2026 earnings on Nov 7, 2025. The consensus estimate for Q2 2026 revenue is $25.86 billion, and the earnings are expected to come in at ...

HYDERABAD, India--(BUSINESS WIRE)--Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Divi’s Laboratories (NSE: DIVISLAB), one of the largest active ...